Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 5Terminated 1

Sponsor Class

OTHER 7INDUSTRY 6

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Dermatologic 6CNS 5Other hematologic neoplasm 3Gastrointestinal 3Myeloid 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Breast 1

Conditions

Carcinoma, Basal Cell 5Medulloblastoma 2Basal Cell Nevus Syndrome 2Skin Neoplasms 1Hematologic Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × sonidegib × Dermatologic × Clear all
NCT04066504 2026-03-18

NISSO

Sun Pharmaceutical Industries Limited

Completed
323 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT00880308 2020-12-19

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
103 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

NCT01208831 2020-12-19

An East Asian Study of LDE225

Novartis

Phase 1 Completed
45 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

NCT01327053 2019-08-28

BOLT

Novartis

Phase 2 Completed
230 enrolled 26 charts
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

NCT02002689 2016-05-02

SIGNATURE

Novartis

Phase 2 Terminated
10 enrolled 9 charts
DermatologicGastrointestinalGynecologicOther hematologic neoplasm

Basal Cell Nevus Syndrome, Colonic Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT01350115 2015-10-19

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Novartis

Phase 2 Completed
10 enrolled 9 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡